REFERENCES
- Reider N, Fritsch P. Other Eczematous Eruptions. In: Bolognia J, Schaffer J, Cerroni L, eds. Dermatology. 4th ed. Philadelphia: Elsevier. 2017;1:228-241.
- Gupta AK, Versteeg SG. Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. Am J Clin Dermatol. 2017;18:193.
- Stein Gold LF, Spelman L, Spellman MC, et al. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis. J Drugs Dermatol. 2015;14:1394.
- Murrell DF, Gebauer K, Spelman L, Zane LT. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study. J Drugs Dermatol. 2015;14:1108.
- Zebda R, Paller AS. Phosphodiesterase 4 (PDE4) Inhibitors. J Am Acad Dermatol. https://www.ncbi.nlm.nih.gov/pubmed/29248522. Accessed December 19, 2017.
- Valia R. Etiopathogenesis of seborrheic dermatitis. Indian J Dermatol Venereol Leprol. 2006;72(4):253.
- McGinley KJ, Leyden JJ, Marples RR, Kligman AM. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol. https://www.ncbi.nlm.nih.gov/pubmed/237965?dopt=Abstract. Published June 1975. Accessed December 19, 2017.
- Faergemann J, Bergbrant I-M, Dohsé M, Scott A, Westgate G. Seborrhoeic dermatitis andPityrosporum(Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol. 2001;144(3):549-556.
- Bergbrant IM. Seborrhoeic dermatitis and Pityrosporum yeasts. Curr Top Med Mycol. https://www.ncbi.nlm.nih.gov/pubmed/8724243?dopt=Abstract. Accessed December 19, 2017.
- Watanabe S, Kano R, Sato H, Nakamura Y, Hasegawa A. The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest Dermatol. https://www.ncbi.nlm.nih.gov/pubmed/11348468. Published May 2001. Accessed December 19, 2017
AUTHOR CORRESPONDENCE
Daniel Aires MD JD daires@kumc.edu.